79 FR 164 pgs. 50658-50659 - Advisory Committee Renewals

Next Article Next

Type: NOTICEVolume: 79Number: 164Pages: 50658 - 50659

Docket number: [Docket No. FDA-2014-N-0001]

FR document: [FR Doc. 2014-20017 Filed 8-22-14; 8:45 am]

Agency: Health and Human Services Department

Sub Agency: Food and Drug Administration

Official PDF Version: PDF Version

Pages: 50658, 50659

[top]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]

Advisory Committee Renewals

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

[top] The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the

charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table.

DATES:

Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology	January 22, 2016.
Gastrointestinal Drugs Advisory Committee	March 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)	March 23, 2016.
	April 5, 2016.
Arthritis Advisory Committee	April 25, 2016.
Pharmacy Compounding Advisory Committee	May 1, 2016.
Anesthetic and Analgesic Drugs Advisory Committee	May 13, 2016.
Blood Products Advisory Committee	May 30, 2016.
Pulmonary-Allergy Drugs Advisory Committee	May 31, 2016.
Drug Safety and Risk Management Advisory Committee	June 2, 2016.
Science Advisory Board to the National Center for Toxicological Research	June 4, 2016.
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 2016.
Psychopharmacologic Drugs Advisory Committee	June 9, 2016.
Transmissible and Spongiform Encephalopathies Advisory Committee	June 26, 2016.
Science Board to the Food and Drug Administration	July 9, 2016.
Allergenic Products Advisory Committee

FOR FURTHER INFORMATION CONTACT:

Michael Ortwerth, Director, Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 1-800-741-8138. For further information related to FDA advisory committees please visit us at: http://www.fda.gov/AdvisoryCommittees/default.htm.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 19, 2014.

Peter Lurie,

Associate Commissioner for Policy and Planning.

[FR Doc. 2014-20017 Filed 8-22-14; 8:45 am]

BILLING CODE 4164-01-P